Radiation Therapy News and Research RSS Feed - Radiation Therapy News and Research

Radiation therapy (also called radiotherapy, x-ray therapy, or irradiation) is the use of a certain type of energy (called ionizing radiation) to kill cancer cells and shrink tumors. Radiation therapy injures or destroys cells in the area being treated (the “target tissue”) by damaging their genetic material, making it impossible for these cells to continue to grow and divide. Although radiation damages both cancer cells and normal cells, most normal cells can recover from the effects of radiation and function properly. The goal of radiation therapy is to damage as many cancer cells as possible, while limiting harm to nearby healthy tissue.
Researchers suggest shorter HF-WBI course as preferred option for early-stage breast cancer patients

Researchers suggest shorter HF-WBI course as preferred option for early-stage breast cancer patients

Early-stage breast cancer patients receiving a shorter course of whole breast radiation with higher radiation doses per fraction reported equivalent cosmetic, functional and pain outcomes over time as those receiving a longer, lower-dose per fraction course of treatment, according to researchers from The University of Texas MD Anderson Cancer Center. [More]
Veterinarian conducts clinical trials to improve cancer treatment for animals, humans

Veterinarian conducts clinical trials to improve cancer treatment for animals, humans

Raelene Wouda's passion for improving cancer treatment starts with our four-legged friends. [More]
Study opens up new strategy to make immunotherapy more effective for different cancer types

Study opens up new strategy to make immunotherapy more effective for different cancer types

By combining local radiation therapy and anti-cancer vaccines with checkpoint inhibitors, researchers from the University of Chicago, working with mice, were able to increase the response rate for these new immunotherapy agents. [More]
LA-NSCLC patients treated at high-volume centers survive longer

LA-NSCLC patients treated at high-volume centers survive longer

Lung cancer is the leading cause of cancer-related death in the United States and is estimated to have contributed to 221,200 new cases and 158,040 deaths in 2015 alone. A secondary analysis of NRG Oncology's clinical trial RTOG 0617, published in the Journal of the National Cancer Institute, was initiated in an effort to evaluate the effect of institution accrual volume on clinical outcomes among patients receiving chemoradiation for locally advanced non-small cell lung cancer (LA-NSCLC). [More]
Two autologous stem-cell transplants improve survival of children with high-risk neuroblastoma

Two autologous stem-cell transplants improve survival of children with high-risk neuroblastoma

Children with high-risk neuroblastoma whose treatment included two autologous stem-cell transplants were more likely to be free of cancer three years later than patients who underwent a single transplant, a Phase 3 clinical trial has found. [More]
Study shows aggressive end-of-life care for young cancer patients may be less effective

Study shows aggressive end-of-life care for young cancer patients may be less effective

In the last month of their lives, younger cancer patients continued to be hospitalized and receive other aggressive treatment at high rates, a University of North Carolina Lineberger Comprehensive Cancer Center-led study found. [More]
Metformin along with chemotherapy/radiation improves outcomes in head and neck cancer patients

Metformin along with chemotherapy/radiation improves outcomes in head and neck cancer patients

Researchers at the University of Cincinnati College of Medicine have found that adding increasing doses of an approved Type 2 diabetes drug, metformin, to a chemotherapy and radiation treatment regimen in head and neck cancer patients is not well tolerated if escalated too quickly, but allowing slower escalation could be beneficial. [More]
Radiation therapy with bevacizumab/pembrolizumab improves outcomes in glioma patients

Radiation therapy with bevacizumab/pembrolizumab improves outcomes in glioma patients

Patients with recurrent high-grade glioma brain tumors have few effective treatment options and the majority of available therapies do not improve survival. Moffitt Cancer Center will present preliminary results from a phase 1 study testing whether the addition of pembrolizumab to radiation therapy and bevacizumab is safe and can control tumor growth for these patients. [More]
Some women with ovarian cancer do not receive beneficial surgical treatment, study finds

Some women with ovarian cancer do not receive beneficial surgical treatment, study finds

Nearly 20 percent of women with ovarian cancer do not undergo surgery, despite it being a standard part of treatment recommendations, according to new research from the Perelman School of Medicine at the University of Pennsylvania. [More]
Combining VCA with organ transplants improves patient outcomes

Combining VCA with organ transplants improves patient outcomes

Simultaneous transplantation of a "composite" skull and scalp flap plus a kidney and pancreas—all from the same donor—provided excellent outcomes for a patient with a non-healing scalp defect and declining organ kidney and pancreas function, according to a report in the June issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons. [More]
Gene expression patterns of normal tissue may predict survival rates of estrogen receptor-positive breast cancer patients

Gene expression patterns of normal tissue may predict survival rates of estrogen receptor-positive breast cancer patients

Breast tissue surrounding tumors could be used to gauge future survival outcomes for women with estrogen receptor-positive breast cancer, a study led by University of North Carolina Lineberger Comprehensive Cancer Center researchers has found. [More]
Clinical trials of anti-cancer agent PAC-1 continue to progress with anonymous funding

Clinical trials of anti-cancer agent PAC-1 continue to progress with anonymous funding

Clinical trials of the anti-cancer agent PAC-1 are continuing to expand, thanks to a $7 million angel investment from an anonymous contributor who originally invested $4 million to help get the compound this far in the drug-approval pipeline. [More]
Radiation-immunotherapy combination can help treat melanoma

Radiation-immunotherapy combination can help treat melanoma

Combining radiation treatments with a new generation of immunotherapies is showing promise as a one-two-punch against melanoma, Loyola Medicine researchers report in a review article. [More]
Conventional repeated radiation treatments may offer no major benefit to brain tumor patients

Conventional repeated radiation treatments may offer no major benefit to brain tumor patients

A new study shows that repeated radiation therapy used to target tumors in the brain may not be as safe to healthy brain cells as previously assumed. [More]
Play-based procedural preparation helps reduce sedation use and costs tied to cranial radiation therapy

Play-based procedural preparation helps reduce sedation use and costs tied to cranial radiation therapy

New research from St. Jude Children's Research Hospital shows support interventions by child life specialists decrease sedation use and costs associated with cranial radiation therapy. [More]
Vessel-sparing radiation, better understanding of prostate anatomy can improve quality of life

Vessel-sparing radiation, better understanding of prostate anatomy can improve quality of life

Remember the game Operation? You need to carefully remove the body part without nicking the sides or the buzzer will sound. [More]
New interactive radiation therapy planning system can help improve patient's chances of recovery

New interactive radiation therapy planning system can help improve patient's chances of recovery

Radiation therapy is one of the most essential elements in cancer treatment. But properly planning radiation therapy is a highly complex task. Fraunhofer mathematicians have joined an alliance with medical physicists and physicians to improve the therapy planning process. In doing so they have helped improve patient's chances of recovery. [More]
Sophisticated technology helps model and simulate optimal dose for pediatric ependymoma patients

Sophisticated technology helps model and simulate optimal dose for pediatric ependymoma patients

St. Jude Children's Research Hospital scientists have used sophisticated pharmacologic modeling and simulation to translate preclinical findings into a successful phase I clinical trial of a chemotherapy agent for treatment of ependymoma. The research marked the first time the approach has been used to calculate drug doses for a clinical trial in pediatric brain tumor patients. [More]
MUSC Hollings Cancer Center receives $8.9 million grant to explore signaling in sphingolipids

MUSC Hollings Cancer Center receives $8.9 million grant to explore signaling in sphingolipids

The Medical University of South Carolina's Hollings Cancer Center received an $8.9 million grant from the National Cancer Institute designed to foster collaboration across clinical and laboratory research for the study of signaling in sphingolipids, a class of lipids known to be involved in the growth of solid tumor cancers. [More]
Patient-oriented online health resources can impact clinical outcomes of pancreatic cancer patients

Patient-oriented online health resources can impact clinical outcomes of pancreatic cancer patients

The Internet has become a powerful and important resource for daily life. When patients receive a medical diagnosis, particularly a difficult one like pancreatic cancer, the web can be an essential information tool, helping to enable patients to have meaningful discussions with health care providers. However, new research from Beth Israel Deaconess Medical Center published today in JAMA Surgery suggests that online information about pancreatic cancer is often written at a prohibitively high reading level and lacks accuracy concerning alternative therapies. [More]
Advertisement
Advertisement